国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (2): 105-108.doi: 10.3760/cma.j.issn.1673-422X.2019.02.010

• 综述 • 上一篇    下一篇

非小细胞肺癌的EGFR-TKI治疗

 龙利丽1, 梁艳玲2, 张兴梅2, 石玉生3   

  1. 1南方医科大学第一临床医学院，广州510515；2南方医科大学基础医学院神经生物学教
    研室，广州510515；3南方医科大学南方医院放疗科，广州510515
  • 出版日期:2019-02-08 发布日期:2019-04-03
  • 通讯作者: 石玉生，Email： zxmray@gmail.com E-mail:zxmray@gmail.com
  • 基金资助:

    国家自然科学基金（81871418）

Treatment of non-small cell lung cancer with EGFR-TKI

Long Lili1, Liang Yanling2, Zhang Xingmei2, Shi Yusheng3   

  1. 1First Clinical Medical College of Southern Medical University, Guangzhou 510515, China; 2Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China; 3Department of Radiotherapy, Southern Hospital, Southern Medical University, Guangzhou 510515, China
  • Online:2019-02-08 Published:2019-04-03
  • Contact: Shi Yusheng, Email: zxmray@gmail.com E-mail:zxmray@gmail.com
  • Supported by:

    National Natural Science Foundation of China (81871418)

PDF

1058

摘要： 表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）是治疗晚期非小细胞肺癌的关键，但后期可产生各种耐药突变。第一、二代EGFR-TKI可显著延长EGFR活化突变型肿瘤患者生存期，第三代EGFR-TKI能有效抑制T790M突变型肿瘤的进展，第四代EGFR-TKI对L858R、T790M突变型和L858R、T790M、C797S突变型肿瘤均有抑制效果。利用循环肿瘤DNA、外泌体RNA能够有效检测EGFR突变类型，可根据突变类型选择EGFR-TKI治疗或联合化疗。

关键词: 癌, 非小细胞肺, 受体, 表皮生长因子, 分子靶向治疗, 表皮生长因子受体酪氨酸酶抑制剂, 耐药性

Abstract: Epidermal growth factor receptortyrosine kinase inhibitors (EGFR-TKIs) are the key to the treatment of advanced nonsmall cell lung cancer (NSCLC), but there are various drugresistant mutations in the latter stage. The first and second generation of EGFRTKIs significantly prolong the survival of patients with EGFR-activated mutant tumors. The third generation of EGFR-TKIs effectively inhibit the progress of T790M mutant tumors. The fourth generation of EGFR-TKIs inhibit both L858R, T790M and L858R, T790M, C797S mutant tumors. Using circulating tumor DNA and exogenous RNA can effectively detect the mutation types of EGFR, and choose EGFR-TKIs therapy or combined chemotherapy according to the mutation types.

Key words: Carcinoma, non-small-cell lung, Receptor, epidermal growth factor, Molecular targeted therapy, Epidermal growth factor receptor-tyrosine kinase inhibitors, Drug resistance